Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
The complement system is primarily a host defence mechanism, but it causes injury to tissue cells through the formation of the membrane attack complex (C5b–C9), which leads to cell lysis and cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results